KR20230008719A - Tno155 및 나자르티닙을 포함하는 약제학적 조합물 - Google Patents

Tno155 및 나자르티닙을 포함하는 약제학적 조합물 Download PDF

Info

Publication number
KR20230008719A
KR20230008719A KR1020227038204A KR20227038204A KR20230008719A KR 20230008719 A KR20230008719 A KR 20230008719A KR 1020227038204 A KR1020227038204 A KR 1020227038204A KR 20227038204 A KR20227038204 A KR 20227038204A KR 20230008719 A KR20230008719 A KR 20230008719A
Authority
KR
South Korea
Prior art keywords
day
amino
egfr
pharmaceutically acceptable
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227038204A
Other languages
English (en)
Korean (ko)
Inventor
화이시앙 하오
첸 리우
수잔 이. 무디
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20230008719A publication Critical patent/KR20230008719A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227038204A 2020-05-08 2021-05-06 Tno155 및 나자르티닙을 포함하는 약제학적 조합물 Pending KR20230008719A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063021772P 2020-05-08 2020-05-08
US63/021,772 2020-05-08
US202063117388P 2020-11-23 2020-11-23
US63/117,388 2020-11-23
PCT/IB2021/053867 WO2021224867A1 (en) 2020-05-08 2021-05-06 Pharmaceutical combination comprising tno155 and nazartinib

Publications (1)

Publication Number Publication Date
KR20230008719A true KR20230008719A (ko) 2023-01-16

Family

ID=75904981

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227038204A Pending KR20230008719A (ko) 2020-05-08 2021-05-06 Tno155 및 나자르티닙을 포함하는 약제학적 조합물

Country Status (12)

Country Link
US (1) US20230172928A1 (https=)
EP (1) EP4146217A1 (https=)
JP (1) JP2023524789A (https=)
KR (1) KR20230008719A (https=)
CN (1) CN115397421A (https=)
AU (1) AU2021267213B2 (https=)
BR (1) BR112022022305A2 (https=)
CA (1) CA3179994A1 (https=)
IL (1) IL297043A (https=)
MX (1) MX2022013867A (https=)
TW (1) TW202207933A (https=)
WO (1) WO2021224867A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112867718B (zh) 2018-09-29 2025-03-04 诺华股份有限公司 用于抑制shp2活性的化合物和组合物的制造
IL305106B2 (en) 2018-09-29 2025-08-01 Novartis Ag Process of manufacture of a compound for inhibiting the activity of shp2
US12441737B2 (en) 2020-07-08 2025-10-14 Novartis Ag Manufacture of compounds and compositions for inhibiting the activity of SHP2
US20250127782A1 (en) 2021-09-08 2025-04-24 Amgen Inc. Methods of treating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CA3048340A1 (en) * 2017-01-10 2018-07-19 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
IL305106B2 (en) * 2018-09-29 2025-08-01 Novartis Ag Process of manufacture of a compound for inhibiting the activity of shp2

Also Published As

Publication number Publication date
BR112022022305A2 (pt) 2022-12-20
CA3179994A1 (en) 2021-11-11
MX2022013867A (es) 2022-11-30
AU2021267213B2 (en) 2023-11-30
AU2021267213A1 (en) 2022-11-03
CN115397421A (zh) 2022-11-25
JP2023524789A (ja) 2023-06-13
EP4146217A1 (en) 2023-03-15
US20230172928A1 (en) 2023-06-08
IL297043A (en) 2022-12-01
WO2021224867A1 (en) 2021-11-11
TW202207933A (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
JP7572958B2 (ja) Ｔｎｏ１５５及びｋｒａｓｇ１２ｃ阻害剤を含む医薬組合せ
US12343344B2 (en) Pharmaceutical combination comprising TNO155 and ribociclib
KR20220148847A (ko) 다브라페닙, erk 억제제, 및 shp2 억제제를 포함하는 삼중 약학적 조합물
AU2021267213B2 (en) Pharmaceutical combination comprising TNO155 and nazartinib
EP3442529B1 (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of lung cancer
CN110996960A (zh) 第三代egfr酪氨酸激酶抑制剂和raf抑制剂的治疗组合
US20240238284A1 (en) Compounds and compositions for the treatment of mpnst
WO2015153866A1 (en) Cancer therapy with ganetespib and an egfr inhibitor
RU2813111C2 (ru) Фармацевтическая комбинация, содержащая tno155 и рибоциклиб
HK40060474A (en) Pharmaceutical combination comprising tno155 and ribociclib
NZ786604A (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of
HK40004472A (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of lung cancer
HK40004472B (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of lung cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902